← Leaderboards
Pingsheng Wu
Vanderbilt University Medical Center
$10,220,667
Attributed
$10,994,410
Total exposure
9
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.1M · FY2006–25$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,388,887 · 8
AHRQ$1,605,523 · 1
By mechanism
R01$9,081,337 · 4
R21$943,048 · 3
RC4$870,323 · 1
F32$99,702 · 1
Top collaborators
- Tina V Hartert2 shared
Most similar at Vanderbilt University Medical Center
Same institution · by research overlap
- Scott Lee$369,888
Others in their field
Top investigators on “Infant”
- Sharon A Nachman · Johns Hopkins University$212,395,175
- Carol Nesel · Westat$188,148,170
- Barbara Driver · Westat, Inc.$184,782,231
- Abhik Das · Research Triangle Institute$178,442,979
- Elizabeth A Thom · George Washington University$170,837,172
- J Brooks Jackson · Social And Scientific Systems, Inc.$150,941,831
Research focus
InfantAsthmaChildMedicaidMorbidity - Disease RateTennesseeRisk FactorsInfancyBirthChildhoodWheezingInfectionLifePopulation BasedHospitalizationRespiratory Syncytial VirusPreventEnrollmentCohortCostPrevalenceProgramsEffectivenessResearch Design
Grant awards (22)
The uptake and real-world effectiveness of emerging respiratory syncytial virus maternal vaccines and monoclonal antibodies on short- and long-term respiratory morbidities$3,304,164
R01 · FY2025 · AI · contact PI
Establishing critical time windows of infant RSV infection in the causal relationship of RSV and childhood asthma$767,578
R01 · FY2025 · HL · contact PI
Establishing critical time windows of infant RSV infection in the causal relationship of RSV and childhood asthma$779,909
R01 · FY2024 · HL · contact PI
The effectiveness of RSV immunoprophylaxis on the short- and long- term respiratory morbidity in children with Down syndrome$448,088
R01 · FY2024 · AI · contact PI
Respiratory morbidity during the pandemic time in individuals with Down syndrome$246,832
R01 · FY2024 · AI · contact PI
The effectiveness of RSV immunoprophylaxis on the short- and long- term respiratory morbidity in children with Down syndrome$451,199
R01 · FY2023 · AI · contact PI
The effectiveness of RSV immunoprophylaxis on the short- and long- term respiratory morbidity in children with Down syndrome$452,517
R01 · FY2022 · AI · contact PI
Electronic cigarette use during pregnancy and the impact on newborn metabolic profile and perinatal health outcomes$241,163
R21 · FY2022 · DA · contact PI
Electronic cigarette use during pregnancy and the impact on newborn metabolic profile and perinatal health outcomes$216,724
R21 · FY2021 · DA · contact PI
The effectiveness of RSV immunoprophylaxis on the short- and long- term respiratory morbidity in children with Down syndrome$1
R01 · FY2021 · AI · contact PI
The effectiveness of RSV immunoprophylaxis on the short- and long- term respiratory morbidity in children with Down syndrome$506,593
R01 · FY2020 · AI · contact PI
The effectiveness of RSV immunoprophylaxis on the short- and long- term respiratory morbidity in children with Down syndrome$518,933
R01 · FY2019 · AI · contact PI
Antibiotic timing, spectrum, and cumulative dose during pregnancy and infancy on risk of asthma$118,500
R21 · FY2017 · HL · contact PI
Antibiotic timing, spectrum, and cumulative dose during pregnancy and infancy on risk of asthma$118,500
R21 · FY2016 · HL · contact PI
RSV immunoprophylaxis impact on RSV morbidity & asthma in healthy preterm infants$112,636
R21 · FY2015 · HL · contact PI
RSV immunoprophylaxis impact on RSV morbidity & asthma in healthy preterm infants$4,165
R21 · FY2015 · HL · contact PI
RSV immunoprophylaxis impact on RSV morbidity & asthma in healthy preterm infants$131,360
R21 · FY2014 · HL · contact PI
Real-world patient responsiveness & safety of long-acting beta agonists in asthma$970,950
R01 · FY2013 · HS · contact PI
Real-world patient responsiveness & safety of long-acting beta agonists in asthma$634,573
R01 · FY2013 · HS · contact PI
Statistical methods for comparative treatment effectiveness using claims data$870,323
RC4 · FY2010 · MH · contact PI
Infant Viral Exposure and Risk of Childhood Asthma$48,796
F32 · FY2007 · HL · contact PI
Infant Viral Exposure and Risk of Childhood Asthma$50,906
F32 · FY2006 · HL · contact PI